Evidence map›Paper›PMID 41942529›Full record

ArticleScientific reports2026

Novel antibody cocktail therapy targeting extracellular tumor-specific mutations to treat EMT6 cell line-derived triple-negative breast cancer.

Stephanie C Pero, Girja S Shukla, Yujing Sun, Ramiro Barrantes-Reynolds, Colin J Hartman, Margaret E Ackerman, Linda Mei, Fan Zhang, Matthew R Fournier, David N Krag

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stephanie C PeroDepartment of Surgery, Larner College of Medicine, University of Vermont, 89 Beaumont Ave, 05405, Burlington, VT, USA.
Girja S ShuklaDepartment of Surgery, Larner College of Medicine, University of Vermont, 89 Beaumont Ave, 05405, Burlington, VT, USA.
Yujing SunDepartment of Surgery, Larner College of Medicine, University of Vermont, 89 Beaumont Ave, 05405, Burlington, VT, USA.
Ramiro Barrantes-ReynoldsVermont Integrative Genomics Resource DNA Facility, University of Vermont, Burlington, VT, USA.
Colin J HartmanThayer School of Engineering, Dartmouth College, Hanover, NH, USA.
Margaret E AckermanThayer School of Engineering, Dartmouth College, Hanover, NH, USA.
Linda MeiDepartment of Surgery, Larner College of Medicine, University of Vermont, 89 Beaumont Ave, 05405, Burlington, VT, USA.
Fan ZhangThe Vermont Biomedical Research Network, University of Vermont, Burlington, VT, USA.
Matthew R FournierDepartment of Surgery, Larner College of Medicine, University of Vermont, 89 Beaumont Ave, 05405, Burlington, VT, USA.
David N KragDepartment of Surgery, Larner College of Medicine, University of Vermont, 89 Beaumont Ave, 05405, Burlington, VT, USA. david.krag@med.uvm.edu.

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
NCI NIH HHS P30 CA023108
6 · The paper itself

Abstract

Treatment options for triple-negative breast cancer (TNBC) remain limited, and the highly heterogeneous nature of these tumors often contributes to therapeutic resistance. While we have previously demonstrated that antibodies targeting multiple distinct mutated cell surface proteins (MSPs) unique to a given tumor can disrupt tumor growth in mice, the feasibility of this approach in TNBC remains uncertain. Here, we used the murine EMT6 cell line to model TNBC and produced polyclonal antibodies (pAbs) targeting 12 different EMT6-specific MSPs. Of these, 9 bound to EMT6 cells in a cumulative manner without detectable non-tumor binding. Administering a cocktail of these 9 MSP-targeting pAbs to EMT6 tumor-bearing mice in combination with anti-PD-1 delayed tumor growth and improved survival. Analyses of TNBC patients in The Cancer Genome Atlas revealed that the tumors of a larger proportion of these patients harbored > 10 MSPs as compared to individuals with other breast cancer types (69% vs. 42%). Together, these results highlight the promise of using antibodies directed against MSPs expressed by TNBC tumor cells to kill tumor cells in vivo, providing a unique approach to individualized cancer patient care with the potential to achieve superior patient outcomes through the elimination of heterogeneous tumor cell populations.

Indexed as

MutationTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCombined Antibody TherapeuticsFemaleHumansMembrane ProteinsMiceXenograft Model Antitumor AssaysCombined Antibody TherapeuticsMembrane ProteinsAntibody-dependent cellular cytotoxicityMutated cell surface protein-targeting antibodiesSomatic missense mutationTriple-negative breast cancerTumor growth inhibition

Identifiers

PMID41942529
PMCPMC13212871

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.